Lucas Lauder

Lucas Lauder

Auto-generated profile, based on publicly available information

Lucas Lauder

University Hospital Basel, University of Basel

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 August 2024 in European Heart Journal
Verified
Journal Article
Closed access
JMJohn William McEvoy
John William McEvoy
CMCian P McCarthy
Cian P McCarthy
RBRosa Maria Bruno
Rosa Maria Bruno
SBSofie Brouwers
Sofie Brouwers
MCMichelle D Canavan
Michelle D Canavan
GKGulnoz Abdusattarovna Khamidullaeva
Gulnoz Abdusattarovna Khamidullaeva

7 November 2022 in European Heart Journal
Verified
Journal Article
Closed access
LLLucas Lauder
Lucas Lauder
FMFelix Mahfoud
Felix Mahfoud
MAMichel Azizi
Michel Azizi
DBDeepak L Bhatt
Deepak L Bhatt
SESebastian Ewen
Sebastian Ewen
MBMicheal Böhm
Micheal Böhm
Arterial hypertension is a leading cause of death globally. Due to ageing, the rising incidence of obesity, and socioeconomic and environmental changes, its incidence increases worldwide. Hypertension commonly coexists with Type 2 diabetes, obesity, dyslipidaemia, sedentary lifestyle, and smoking leading to risk amplification. Blood pressure lowering by lifestyle modifications and antihypertensive drugs reduce cardiovascular (CV) morbidity and mortality. Guidelines recommend dual- and triple-combination therapies using renin–angiotensin system blockers, calcium channel blockers, and/or a diuretic. Comorbidities often complicate management. New drugs such as angiotensin receptor-neprilysin inhibitors, sodium–glucose cotransporter 2 inhibitors, glucagon-like peptide-1 receptor agonists, and non-steroidal mineralocorticoid receptor antagonists improve CV and renal outcomes. Catheter-based renal denervation could offer an alternative treatment option in comorbid hypertension associated with increased sympathetic nerve activity. This review summarises the latest clinical evidence for managing hypertension with CV comorbidities.

12 May 2023 in Nature Reviews Cardiology
Verified
Journal Article
Closed access
PDF file
FGFelix Götzinger
Felix Götzinger
LLLucas Lauder
Lucas Lauder
ASAndrew S. P. Sharp
Andrew S. P. Sharp
ILIrene M. Lang
Irene M. Lang
SRStephan Rosenkranz
Stephan Rosenkranz
FMFelix Mahfoud
Felix Mahfoud

12 November 2024 in Circulation
Verified
Journal Article
Closed access
DVDavor Vukadinović
Davor Vukadinović
LLLucas Lauder
Lucas Lauder
DKDavid E. Kandzari
David E. Kandzari
DBDeepak L Bhatt
Deepak L Bhatt
AKAjay J. Kirtane
Ajay J. Kirtane
FMFelix Mahfoud
Felix Mahfoud
BACKGROUND: Several sham-controlled trials have investigated the efficacy and safety of catheter-based renal denervation (RDN) with mixed outcomes. We aimed to perform a comprehensive meta-analysis of all randomized, sham-controlled trials investigating RDN with first- and second-generation devices in hypertension. METHODS: We searched MEDLINE and the Cochrane Library for eligible trials. Outcomes included both efficacy (24-hour and office systolic [SBP] and diastolic blood pressure [DBP]) and safety (all-cause death, vascular complication, renal artery stenosis >70%, hypertensive crisis) of RDN. We performed a study-level, pairwise, random-effects meta-analysis of the summary data. RESULTS: Ten trials comprising 2478 patients with hypertension while being either off or on treatment were included. Compared with sham, RDN reduced 24-hour and office systolic blood pressure by 4.4 mm Hg (95% CI, 2.7 to 6.1; P <0.00001) and 6.6 mm Hg (95% CI, 3.6 to 9.7; P <0.0001), respectively. The 24-hour and office diastolic blood pressure paralleled these findings (–2.6 mm Hg [95% CI, –3.6 to –1.5]; P <0.00001; –3.5 mm Hg [95% CI, –5.4 to –1.6]; P =0.0003). There was no difference in 24-hour and office systolic blood pressure reduction between trials with and without concomitant antihypertensive medication ( P for interaction, 0.62 and 0.73, respectively). There was no relevant difference in vascular complications (odds ratio, 1.69 [95% CI, 0.57 to 5.0]; P =0.34), renal artery stenosis (odds ratio, 1.50 [95% CI, 0.06 to 36.97]; P =0.80), hypertensive crisis (odds ratio, 0.65 [95% CI, 0.30 to 1.38]; P =0.26), and all-cause death (odds ratio, 1.76 [95% CI, 0.34 to 9.20]; P =0.50) between RDN and sham groups. Change of renal function based on estimated glomerular filtration rate was comparable between groups ( P for interaction, 0.84). There was significant heterogeneity between trials. CONCLUSIONS: RDN safely reduces ambulatory and office systolic blood pressure/diastolic blood pressure versus a sham procedure in the presence and absence of antihypertensive medications.

7 December 2022 in European Heart Journal
Verified
Journal Article
Open access
PDF file
MBMicheal Böhm
Micheal Böhm
Stefan D. AnkerStefan D. Anker
Stefan D. Anker
FMFelix Mahfoud
Felix Mahfoud
LLLucas Lauder
Lucas Lauder
GFGerasimos Filippatos
Gerasimos Filippatos
JBJaved Butler
Javed Butler
Empagliflozin reduces the risk of cardiovascular death or heart failure (HF) hospitalization in patients with HF and preserved ejection fraction. This study aims to evaluate if systolic blood pressure (SBP) moderates these effects. The association of SBP and the treatment effects of empagliflozin in EMPEROR-Preserved (empagliflozin outcome trial in patients with chronic heart failure with preserved ejection fraction) was evaluated. Randomized patients (n = 5988) were grouped according to SBP at baseline ( 130 mmHg, n = 3118). The effect of empagliflozin on blood pressure, cardiovascular death or HF hospitalization (primary outcome), total HF hospitalizations, and rate of decline in estimated glomerular filtration rate was studied. Over a median of 26.2 months, the placebo-corrected decline was small and not significantly different across baseline SBP. On placebo, the risk of cardiovascular death or hospitalization for HF was 8.58 at >130 mmHg, 8.26 at 110–130 mmHg, and 11.59 events per 100 patient-years at 130 mmHg, P = 0.08 vs. 110–130 mmHg). There was no evidence for baseline SBP moderating the effect of empagliflozin on risk of HF events (primary endpoint interaction P = 0.69, recurrent HF hospitalizations interaction P = 0.55). When comparing empagliflozin with placebo, SBP did not meaningfully associate with adverse events such as hypotension, volume depletion, and acute renal failure. In EMPEROR-Preserved, empagliflozin was effective and safe without SBP meaningfully moderating empagliflozin’s treatment effects. This analysis of EMPEROR-Preserved shows that empagliflozin can be used safely and effectively without blood pressure being a meaningful moderator of the drug benefit. URL: https://www.clinicaltrials.gov Unique identifier: NCT03057951 Effect of empagliflozin on blood pressure and outcomes. Effect of empagliflozin on systolic blood pressure (SBP) according to baseline SBP (top), effect of Empa on the primary outcome over the spectrum of baseline SBP (middle), and effect of Empa on the slope of change in estimated glomerular filtration rate (adjusted mean difference, mL/min/1.73 m2/year) (bottom).

1 August 2023 in Hypertension
Verified
Journal Article
Open access
FMFelix Mahfoud
Felix Mahfoud
Giuseppe ManciaGiuseppe Mancia
Giuseppe Mancia
RSRoland E. Schmieder
Roland E. Schmieder
LRLuis M. Ruilope
Luis M. Ruilope
KNKrzysztof Narkiewicz
Krzysztof Narkiewicz
MBMicheal Böhm
Micheal Böhm
BACKGROUND: The Global SYMPLICITY Registry DEFINE (Denervation Findings in Real World) investigates radiofrequency renal denervation (RDN) in a broad range of patients with hypertension. We evaluated whether the number or type of antihypertensive medications were associated with increased long-term blood pressure (BP) reductions and cardiovascular outcomes following radiofrequency RDN. METHODS: Patients underwent radiofrequency RDN and were categorized by baseline number (0–3 and ≥4) and different combinations of medication classes. BP changes were compared between groups through 36 months. Individual and composite major adverse cardiovascular events were analyzed. RESULTS: Of 2746 evaluable patients, 18% were prescribed 0 to 3 and 82% prescribed ≥4 classes. At 36 months, office systolic BP significantly decreased ( P <0.0001) by −19.0±28.3 and −16.2±28.6 mm Hg in the 0 to 3 and ≥4 class groups, respectively. Twenty-four–hour mean systolic BP significantly decreased ( P <0.0001) by −10.7±19.7 and −8.9±20.5 mm Hg, respectively. BP reduction was similar between the medication subgroups. Antihypertensive medication classes decreased from 4.6±1.4 to 4.3±1.5 ( P <0.0001). Most decreased (31%) or had no changes (47%) to the number of medications, while 22% increased. The number of baseline antihypertensive medication classes was inversely related to the change in prescribed classes at 36 months ( P <0.001). Cardiovascular event rates were generally low. More patients in the ≥4 compared with 0 to 3 medication classes had myocardial infarction at 36 months (2.8% versus 0.3%; P =0.009). CONCLUSIONS: Radiofrequency RDN reduced BP safely through 36 months, independent of the number and type of baseline antihypertensive medication classes. More patients decreased than increased their number of medications. Radiofrequency RDN is a safe and effective adjunctive therapy regardless of antihypertensive medication regimen. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT01534299.